A clinical study of the combination of Tuoyi (toripalimab) and STP-705 (cotsiranib) for the treatment of advanced Melanoma
Latest Information Update: 15 Jan 2020
At a glance
- Drugs STP 705 (Primary) ; Toripalimab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
Most Recent Events
- 15 Jan 2020 New trial record
- 13 Jan 2020 According to a Sirnaomics media release, this trial will be conducted under a strategic collaboration between Sirnaomics and Shanghai Junshi Biosciences Co., Ltd to test the combination of STP-705 and Toripalimab for the treatment of advanced melanoma.